JULIE OMISHAKIN: Open Payments
NPI 1962748954 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 19 payments from 12 companies in 2025. Trend: 2023 $831 · 2024 $701 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $204 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| ABBVIE INC. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| ViiV Healthcare Company | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Exact Sciences Corporation | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: Descovy, INVEGA SUSTENNA, MAVYRET, AREXVY, APRETUDE, INGREZZA, Rybelsus, GARDASIL 9.
Industry payments across CA — which companies pay providers there.
